However, clinical trials have demonstrated worse tumor control in HNSCC patients treated with EPO and found that EPO can promote lymphatic tract metastasis in HNSCC through mediated activation of JAK-STAT signaling, thereby enhancing tumor aggressiveness, which is detrimental to patient prognosis (Lai et al., 2005). This evidence concerns the gene EPO and neoplasm.